Zenotech Laboratories (BOM:532039) 3-Year Share Buyback Ratio : 0.00% (As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Zenotech Laboratories's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Zenotech Laboratories's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 13 years, Zenotech Laboratories's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -18.90%. And the median was -18.90%.

BOM:532039's 3-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -2.2
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Zenotech Laboratories's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenotech Laboratories's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Zenotech Laboratories's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Zenotech Laboratories 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Zenotech Laboratories (BOM:532039) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Zenotech Laboratories 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Zenotech Laboratories's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenotech Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » 3-Year Share Buyback Ratio

Traded in Other Exchanges

N/A

Address

Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078

Website

http://zenotechlab.com

Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories Headlines

No Headlines